Leerink Partnrs Has Bullish Outlook for HIMS FY2024 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Leerink Partnrs upped their FY2024 earnings per share estimates for shares of Hims & Hers Health in a research note issued to investors on Tuesday, October 29th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.23 per share for the year, up from their prior estimate of $0.22. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s FY2027 earnings at $0.91 EPS.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. The business’s revenue was up 51.8% compared to the same quarter last year.

Other equities research analysts have also issued reports about the company. Piper Sandler restated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Truist Financial increased their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. TD Cowen increased their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Bank of America increased their price objective on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus target price of $20.21.

Hims & Hers Health Price Performance

HIMS stock opened at $20.37 on Thursday. The business has a 50 day simple moving average of $18.01 and a 200-day simple moving average of $18.06. The firm has a market capitalization of $4.38 billion, a PE ratio of 254.66 and a beta of 1.06. Hims & Hers Health has a 1 year low of $5.97 and a 1 year high of $25.74.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $16.47, for a total value of $3,110,985.36. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $551,777.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $551,777.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,334 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20. Following the transaction, the insider now owns 164,475 shares in the company, valued at $2,845,417.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 858,665 shares of company stock worth $15,148,890. 17.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at $5,531,000. Diversify Advisory Services LLC bought a new position in Hims & Hers Health in the 1st quarter worth $701,000. International Assets Investment Management LLC bought a new position in Hims & Hers Health in the 3rd quarter worth $6,790,000. Sei Investments Co. raised its holdings in Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after acquiring an additional 37,890 shares during the period. Finally, Quantbot Technologies LP raised its holdings in Hims & Hers Health by 3,444.9% in the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after acquiring an additional 208,621 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.